RxDoctor Payments Data

Rajiv Handa, MD

Clinical Cardiac Electrophysiology · Saint Louis, MONPI 1790783538

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (48.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Philips North America LLC at 43.7% of the total. Reporting peaked in 2021 at $10,755 and has fallen 81.2% since, to $2,027 in 2025.

$22,372in general payments, 2019–2025

Across 504 payments — averaging $44.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$10K
  • Boston Scientific$3K
  • Abbott$2K
  • Medtronic$2K
  • Biosense Webster, Inc.$1K
  • Johnson & Johnson$1K
  • plus $3K from 13 others

What the payments were for

  • Consulting fees$9,40042%
  • Speaking & faculty fees$3502%
  • Travel & lodging$1,7518%
  • Food & beverage$10,85849%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,372 in reported general payments places this provider in the 60th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

See all clinical cardiac electrophysiology providers in Missouri

Medicare billing

Part B allowed, 2024
$226,459
Medicare patients
1,923
Services billed
4,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban616$542,247
XareltoRivaroxaban223$192,606
MultaqDronedarone Hcl97$115,745
Dofetilide83$15,247
Mexiletine Hcl44$5,508
Amiodarone Hcl416$5,418
Dabigatran EtexilateDabigatran Etexilate Mesylate18$4,608
SotalolSotalol Hcl182$4,296
Metoprolol Succinate272$3,319
Diltiazem 24hr Er (Cd)Diltiazem Hcl53$2,057
Verapamil SrVerapamil Hcl18$1,549
Flecainide Acetate12$687
Metoprolol Tartrate62$519
Verapamil ErVerapamil Hcl14$348
Dilt-XrDiltiazem Hcl17$178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$662$542,247616 claims
Johnson & JohnsonXarelto$1,006$192,606223 claims
Sanofi-aventis U.S. LLCMultaq$192$115,74597 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

Other clinical cardiac electrophysiology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →